查看文章

Tyrosine kinase inhibitors (TKIs) are effective in the targeted treatment of various malignancies. KIs including small molecue KIs and monoclonal antibodies directed against kinases, have emerged over the past decade as an important class of anticancer agents. Imatinib was the first to be introduced into clinical oncology, and it was followed by drugs such as gefitinib, erlotinib, sorafenib, sunitinib, and dasatinib. TKIs are also called tyrphostins, the short name for “tyrosine phosphorylation inhibitor”, originally coined in a 1988 publication, which was the first description of compounds inhibiting the catalytic activity of the epidermal growth factor receptor (EGFR). Nibs are either in dosage form, blood serum, or biological fluids. This paper reviewes the reported analytical methods for the determination of Dasatinib, Lapatinib, Sorafenib, Imatinib, Nintedanib, Sunitinib, Pazopanib individually or in combination with other drugs are represented in tables 2-8. Table 9 is concerned with the reported methods for the combination of different members of Nibs.